How to appeal a Cigna compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics

Cited policy: Cigna Coverage Policy: Compounded Medications

Compounded medication covered when (a) no commercial alternative exists at the required dose / route, (b) patient cannot tolerate commercial form, or (c) FDA shortage. Pediatric weight-based dosing requiring liquid formulation specifically recognized.

How Cigna denies compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics — and how to counter it

Where Cigna pushes back: 1) Commercial strength deemed close enough; 2) Pediatric liquid alleged 'convenience' rather than necessity; 3) Pharmacy 503 status not on file.

Counter-arguments that hold up: Document patient weight, weight-based mg/kg dose, and the absence of any commercial strength matching the prescribed dose (typically need exact mg or mg/mL). For young children unable to swallow solid dosage forms, oral liquid is medically required (FDA Pediatric Formulation Initiative; Marraffa PPT 2010). Submit pharmacy state license + USP 795 compliance + PCAB if applicable. Cite state pharmacy law on pediatric compounding.

What Cigna typically denies for compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the compounded medications (non-glp-1) — bhrt, ldn, ketamine, custom-dose pediatrics treatments most often flagged for prior auth, step therapy, or medical necessity review:

• BHRT compounded
• Bi-Est cream
• Compounded testosterone
• Compounded progesterone
• Low-dose naltrexone (LDN)
• Compounded ketamine

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.